Cemsidomide - C4 Therapeutics
Alternative Names: CFT 7455Latest Information Update: 14 Dec 2023
At a glance
- Originator C4 Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action IKZF1 protein degraders; IKZF3 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 14 Dec 2023 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Multiple myeloma and non-Hodgkin's Lymphoma released by C4 Therapeutics
- 14 Nov 2022 Chemical structure information added
- 12 Apr 2022 Efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a phase I/II trial in Multiple myeloma and non-Hodgkin's Lymphoma released by C4 Therapeutics